The nation’s innovative drug out-licensing deals reached US$130 billion by the end of September, almost matching 2025’s full-year level.
The nation’s innovative drug out-licensing deals reached US$130 billion by the end of September, almost matching 2025’s full-year level.
The U.S. is drafting rules for biopharma firms investing in China that would likely maintain their ability to ink most licensing deals for Chinese drugs. Read more here.
This is the newest page. Registered accounts read further back.